Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Chiasma Raises $38.5 Million for Late-Stage Trial of Oral Drug

By David Wainer July 24 (Bloomberg) -- Chiasma Ltd., which develops oral drugs previously only available through injection, raised $38.5 million to fund a late-stage trial of the Octreolin growth- disorder treatment and a study of a second medicine. The equity financing round was led by Abingworth, which invests in the health-care sector, and current investor MPM Capital, the Jerusalem-based company said in a press release. The late-stage trial should be completed in the second quarter of 2013, Chiasma said. Acromegaly, known in children as gigantism, is a rare condition in which overproduction of growth hormone causes the face to become coarse and the hands and feet to swell. About 20,000 patients are eligible for Octreolin treatment in the U.S. and Europe, with an additional 10,000 patients in the rest of the world, according to Chiasma. The U.S. Food and Drug Administration granted orphan-drug designation for Octreolin, meaning the product would get seven years of market exclusivity if approved, Chiasma said. Chiasma is also developing an oral treatment for a chronic kidney disease complication, it said. For Related News and Information: Bloomberg drug database: BDRG Market map of the TA-25 index: TA-25 IMAP --Editors: Kristen Hallam, Thomas Mulier To contact the reporter on this story: David Wainer in Tel Aviv at +972-3-542-7110 or dwainer3@bloomberg.net To contact the editor responsible for this story: Phil Serafino at +33-1-5530-6277 or pserafino@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.